HOME ASBESTOS DRUGS POLLUTANTS ACCIDENTS MALPRACTICE STORY OF OUR FIRM SEARCH

Poland- Mesothelioma Publication

This is a Mesothelioma abstract of an article about published at PubMed by the NIH.

Pneumonol Alergol Pol. 2004;72(5-6):221-5.

[Diagnostic difficulties in primary mesothelioma]

Khalil LY, Szturmowicz M, Wawrzynska L, Fijalkowska A, Kupis W, Maszkowska-Kopij K, Szczepulska E, Burakowska B, Tomkowski W, Torbicki A.

Kliniki Chorob Wewnetrznych Klatki Piersiowej, Instytutu Gruzlicy i Chorob Pluc, w Warszawie.

A 54-year-old woman with a history of fatigue and shortness of breath was found to have a pericardial effusion and mild mediastinal lymphadenopathy. Video-assisted pericardioscopy revealed thickened pericardium studded with multiple nodules. Histologically the tumor was diagnosed as papillary adenocarcinoma. The site of the primary tumor could not be identified. As lung cancer is one of the most frequent causes of pericardial metastases the patient was treated with cisplatin and vinblastin. Following 5 courses of chemotherapy--given over a 4 month period--the amount of pericardial effusion and pericardial thickness did not change. The material from pericardial biopsy was reexamined and positive immunostaining for calretinine was found. The final diagnosis was primary pericardial mesothelioma of epithelioid type. Palliative radiotherapy of mediastinum was planned but the patient deteriorated and died due to disease progression with venous thrombosis and superior vena cava syndrome. The case illustrates the difficulties in establishing diagnosis of primary pericardial mesothelioma which is a rare tumor with poor prognosis.


PMID: 15757264 [PubMed - in process]

For additional information about our mesothelioma lawyers and a complimentary consultation, speak to a Client Relations representative at Weitz & Luxenberg today! Please fill out this simple form, call toll free 1 (800) 476-6070 or e-mail us at Clientrelations@weitzlux.com.

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

TABLE OF CONTENTS
Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos


IN THIS SECTION
Farnesyltransferase Inhibitors
Cancer Immunotherapy
Great Britain
Poland
Pemetrexed Therapy
Sv40 Specific Recall Immunity
Polish Cases
Extra Pleural Pneumonectomy
Intraoperative Radiation Therapy
Calretinin
Hyaluronan
Granulocyte Colony Stimulating Factor
Canada
Pemetrexed (Alimta)
Calretinin Antibodies
Greece
Neoplasia
FDA Pemetrexed
Secreted Frizzled Related Protein
Tumor Necrosis
Podoplanin
Lymphohistiocytoid
Pathogenesis of Malignant Pleural
Diagnostic Difficulties
Mesothelioma from Adenocarcinoma
Mesothelial Proliferation
ThinPrep Cytospin
Effusion
Chemotherapy Options
Heparanase
Malignant Deciduoid
Mortality
Pemetrexed in Malignant Pleural Mesothelioma
Pleural Mesothelioma
Prognostic Analysis
Italian Mortality Rates
Vinorelbine and Oxaliplatin
DNA Methylation Profiles
Primary Malignant Pericardial Mesothelioma
Abdominal CAT Scans
China
Disseminated Malignant
Statistical Validation
Pathogenesis
Lung Adenocarcinoma
Japan


RETURN BACK TO
Mesothelioma
Latest News
see also:

Podoplanin Mesothelioma Publication - Podoplanin
Know more about Mesothelioma and Podoplanin

Hyaluronan Mesothelioma Publication speaks about Hyaluronan
Mesothelioma article published at PubMed by NIH about Hyaluronan

Mesothelioma National Institute Health Publication The National Institute of Health Mesothelioma Research Publications
Mesothelioma Publications from the National Institute of Health